BioSpace News Archive

Leap Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2021.

Spectrum Pharmaceuticals today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corporate update on Thursday, March 17, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx ® -Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity.

Tiziana Life Sciences Ltd announced today that it will host a virtual Key Opinion Leader (KOL) webinar event, “Foralumab Clinical Update in Multiple Sclerosis: A Landmark Study with Intranasal Immunotherapy” on Monday, March 14, 2022 at 11:00 am Eastern Time.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor call on March 14, 2022, at 8:00 AM ET to discuss data from its Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i).

Natera, Inc. announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, multi-center trial to measure the clinical impact of serial testing with Signatera in resectable CRC.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

ProSomnus Sleep Technologies, the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea, announced the results of four studies evaluating its oral appliance therapy devices as an alternative to continuous positive airway pressure therapy in treating OSA.

Agile Therapeutics, Inc., a women’s healthcare company, announced that Chairman and Chief Executive Officer Al Altomari will participate in two upcoming investor conferences, including a live panel discussion on drug development in Women’s Health.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 13-16 in Nashville, Tenn. and virtually.